10:06 AM EDT, 09/23/2025 (MT Newswires) -- Illumina ( ILMN ) said Tuesday it is working with several global drugmakers to develop companion diagnostics on its TruSight Oncology test to target KRAS mutations.

The company said the partnerships aim to expand diagnostic claims that can help match cancer patients with targeted treatments and clinical trials.

KRAS is among the most frequently altered oncogenes, and identifying its variants is considered critical for selecting appropriate therapies, according to the company.

Illumina ( ILMN ) said the initiative builds on its pipeline of companion diagnostics under development with pharmaceutical companies.

Price: 102.34, Change: +0.85, Percent Change: +0.84